Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy

Authors

  • T. M. Goszczyński,

    Corresponding author
    1. “Neolek” Laboratory, Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland
    • Correspondence

      Tomasz M. Goszczyński, “Neolek” Laboratory of Biomedical Chemistry, Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Rudolf Weigl St., 53-114 Wrocław, Poland. Tel: +48 713371172 (ext. 242); Fax: +48 713372171; E-mail: goszczynski@iitd.pan.wroc.pl

    Search for more papers by this author
  • B. Filip-Psurska,

    1. “Neolek” Laboratory, Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland
    Search for more papers by this author
  • K. Kempińska,

    1. “Neolek” Laboratory, Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland
    Search for more papers by this author
  • J. Wietrzyk,

    1. “Neolek” Laboratory, Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland
    Search for more papers by this author
  • J. Boratyński

    1. “Neolek” Laboratory, Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland
    Search for more papers by this author

Abstract

At present, effective anticancer therapy remains one of the most challenging tasks facing the scientific community. A major limitation to most conventional low-molecular weight anticancer chemotherapeutics is their unfavourable uptake by healthy tissue, fast metabolism and lack of tumour cell selectivity. One way to solve this problem is the application of hybrid nanoparticles containing widely known therapeutic substances. This study was performed with the aim of investigating the potential of use hydroxyethyl starch (HES) as a high-molecular weight carrier for anticancer drug (methotrexate, MTX). HES-MTX conjugates were characterized in terms of MTX content, hydrodynamic size, zeta potential, and drug release kinetics. In vitro biological characteristics were determined using different cancer cell lines. The antitumor effect in vivo was tested in NOD/SCID mice subcutaneously inoculated with MV-4-11 human leukaemia cells and CDF1 mice intraperitoneally inoculated with P388 murine leukaemia cells. The in vivo experiments revealed the considerably higher antitumor efficacy of HES-MTX conjugates in comparison to unconjugated drug. The results presented in this article demonstrate that the application of HES as an anticancer drug carrier can improve the treatment efficacy and have significant implications for the future design and implementation of drug-carrier conjugates. The study should help create new opportunities in the design of HES-based innovative drug-carrier conjugates.

Ancillary